Skip to Content

See Also:

VICC toll-free number 1-877-936-8422

Vincent L. Giranda, M.D., Ph.D.

Senior Project Leader
Professor of Cancer Biology

Contact Information:

Abbott Laboratories, D47S, AP9A
100 Abbott Park Road
Abbott Park, IL 60064-6117

Abbott Labs: Project Leader for cell cycle, apoptosis, and DNA repair research efforts where I lead a multidisciplinary team of scientists in discovering novel pharmacological agents. These inhibitors are expected to diminish the growth and spread of human cancers. Other scientific contributions also included work in papillomavirus, cytomegalovirus, and influenza virus research. Line responsibility for 23 scientists (synthetic chemistry, biochemistry, enzymology, cell & molecular biology, pharmacokinetics, pharmacodynamics & biomarkers) on the project. Project responsibility for another 10-20 scientist in the matrix organization (in vivo pharmacology, toxicology, x-ray crystallography, nmr spectroscopy, genomics & proteomics, combinatorial chemistry, high-throughput screening).

Eastman Kodak/ Sterling Winthrop: Project leader for the anti-thrombin team. Thrombin inhibitors were considered for anti-thrombotic as well as anti-metastatic purposes. Using a structure based approach and starting from a poor screening hit, we rapidly produced compounds with Ki < 20 pM and good pharmacokinetic profiles. Also, I continued and extended the picornavirus structural work. This work aided in the discovery of pleconaril, now in human clinical trials. Supervised approximately 30 scientists in the thrombin inhibitor project, in a matrix organization.

Purdue University: Investigated the mechanism of action of the capsid binding class of anti-picornaviral compounds in the laboratory of Michael Rossmann. Atomic resolution structural studies were performed on whole viruses, either wild type or mutants, in the presence or absence of inhibitors. These mutant and drug studies along with a novel "real time" crystallographic technique led to the identification of the molecular switch region in the rhinoviral capsid. It is with this switch that the capsid binding compounds interfere, thus inhibiting viral uncoating.

  • Temple University, Phila., PA Ph.D. 1989
  • Temple University, Phila., PA M.D. 1987
  • PA State Univ, State College,PA BS 1981